Inmarsat Unveils the Communications Network of the Future
29.7.2021 12:47:00 EEST | Business Wire | Press release
Today, Inmarsat unveiled plans for ORCHESTRA, the communications network of the future. In the largest ever transformation of its current world-class services, Inmarsat ORCHESTRA will bring together existing geosynchronous (GEO) satellites with low earth orbit satellites (LEO) and terrestrial 5G into an integrated, high-performance solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005443/en/
Inmarsat unveils ORCHESTRA, the communications network of the future (Graphic: Business Wire)
Whether for a ship in a crowded port, an aircraft preparing to land at LAX, or a defence force deployed in a remote location, ORCHESTRA is designed to meet evolving connectivity needs in the mobility market with a service unmatched by any competitor offering, planned or in existence.
“An orchestra brings different instruments together, each supporting the other and playing its role in the masterpiece. We’re building ORCHESTRA on the same concept,” said Rajeev Suri, CEO of Inmarsat. “By combining the distinct qualities of GEO, LEO and 5G into a single network, we will deliver a service that is far greater than the sum of its parts. Our customers will benefit from dramatically expanded high throughput services around the world. This is the future of connectivity and Inmarsat is perfectly positioned to bring it to the world with its proven technology expertise, right base of customers and partners, and financial strength.”
ORCHESTRA will open up a host of new and previously unattainable possibilities for industries across the world. New services include close-shore navigation for autonomous vessels, next-generation emergency safety services for maritime crews, secure and tactical private networks for governments and direct-to-cloud connections for airlines. New segments set to benefit from ORCHESTRA include energy rigs and drilling platforms, mid-market business aircraft, coastal vessels, smart passenger ships and urban air mobility.
ORCHESTRA is unique because it draws together the benefits of multiple technologies to create one cohesive solution. LEO, GEO and terrestrial networks have never been combined at scale before to create a unified connectivity service for mobility customers. The result is a ‘dynamic mesh network’ that will deliver high-performance connectivity everywhere. Bringing together the lowest average latency and fastest average speeds with unique resilience, ORCHESTRA will eliminate the industry-wide challenge of congested network ‘hot spots’.
Inmarsat’s existing GEO satellites – both GX and L-band - will continue to provide global coverage, high performance, security and resilience. Terrestrial 5G adds ultra-high capacity in busy ‘hot spots’, such as ports, airports, and sea canals. A small constellation of LEO satellites will layer additional high capacity over further high-demand areas such as oceanic flight corridors. As a result, the network will offer the highest capacity for mobility users worldwide, and at ‘hot spots’.
The network will benefit from ‘dynamic mesh’ technology, which allows individual customer terminals to direct traffic to and from other customer terminals. This means that a ship within reach of a 5G ground station can receive ample capacity for its own needs as well as route capacity onwards to other vessels beyond terrestrial reach. This effectively creates a mobile web of terminals that extend the network’s reach and improve its performance and resilience.
“ORCHESTRA ensures Inmarsat is well positioned to deliver long-term, profitable growth by delivering new services to existing customers, targeting near-adjacent market segments, and maintaining a strong competitive position,” said Suri. “We have a record of adopting the right technology at the right time. We plan to focus initially on delivering the ORCHESTRA terrestrial network, while preparing for a future LEO constellation in the range of 150-175 satellites. This is a highly cost-effective approach that leverages Inmarsat’s leading GEO satellite networks as part of ORCHESTRA’s unique multi-layer architecture.”
The new approach means that Inmarsat can easily boost capacity in high-density areas such as ports and airports, ensuring customer needs continue to be met well into the future with capacity scaled directly to match their requirements. The initial five-year (2021-2026) total investment for ORCHESTRA is expected to be in the order of $100m.
ENDS
About Inmarsat
Inmarsat is the world leader in global, mobile satellite communications. It owns and operates the world’s most diverse global portfolio of mobile telecommunications satellite networks, and holds a multi-layered, global spectrum portfolio, covering L-band, Ka-band and S-band, enabling unparalleled breadth and diversity in the solutions it provides. Inmarsat’s long-established global distribution network includes not only the world’s leading channel partners but also its own strong direct retail capabilities, enabling end to end customer service assurance.
The company has an unrivalled track record of operating the world’s most reliable global mobile satellite telecommunications networks, sustaining business and mission critical safety & operational applications for more than 40 years. It is also a major driving force behind technological innovation in mobile satellite communications, sustaining its leadership through a substantial investment and a powerful network of technology and manufacturing partners.
Inmarsat operates across a diversified portfolio of sectors with the financial resources to fund its business strategy and holds leading positions in the Maritime, Government, Aviation and Enterprise satcoms markets, operating consistently as a trusted, responsive and high-quality partner to its customers across the globe.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005443/en/
Contact information
Jonathan Sinnatt/ Matthew Knowles
Corporate Communications
Tel: +44 (0)20 7728 1518/1355
press@inmarsat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
